Divestment wave continues as pharma banks on delivery systems

The wave of divestures sweeping the pharmaceutical industry continues following the most recent announcements by SurModics and Pfizer (see the April 19, 2011 LRTJ). Beleaguered drug delivery company SurModics recently announced the sale of its pharmaceutical assets, which include injectable delivery...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

Singaporean precision medicine startup Hummingbird Bioscience nets $125 million in Series C funding led by Novo Holdings

News Commentary | May 24, 2021

This will further expand Hummingbird's proprietary Rational Antibody Discovery (RAD) platform for novel therapeutic monoclonal antibodies. The market for therapeutic antibodies is rapidly growing, as new drugs have been approved for treating various human diseases, including many cancers and ... Not part of subscription

Hawthorne Effect nets $20 million Series A round to further its efforts in optimizing clinical trials

News Commentary | June 18, 2021

Hawthorne Effect aims to alleviate challenges in patient recruitment and retention through decentralizing trials. Its technology platform manages key aspects of the clinical trial journey for patients and investigators, from recruitment to study exit, including visit choreography, data acquisition, ... Not part of subscription

Pfizer will acquire Trillium Therapeutics for $2.26 billion, seeking to further boost its capabilities in oncology

News Commentary | August 27, 2021

Trillium is a developer of a novel immunotherapy solution that targets a molecule called CD47 on cancer cells. In healthy cells, CD47 plays a part in displaying a "don't‑eat‑me" signal to the immune system. Malignant cancer cells display these molecules on their surface to evade the immune system. ... Not part of subscription